Advertisement

Advertisement

Direct From ASCO

Prostate Cancer

Rapid Guideline Update on Radiotracers for Determining Radioligand Treatment Eligibility in Metastatic Castration-Resistant Prostate Cancer

Brandon May  /  February 25, 2024

ASCO has released a guideline rapid recommendation update addressing radiotracers used for prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) diagnostic imaging for selecting patients with metastatic castration-resistant prostate cancer (mCRPC) to receive lutetium-177–label...

Issues in Oncology

ASCO Welcomes New Rule Establishing Electronic Prior Authorization in Federal Health Plans

ASCO  /  February 25, 2024

On January 17, the Centers for Medicare & Medicaid Services (CMS) issued its rule requiring federal health plans—including Medicare Advantage plans, Medicaid plans, and Qualified Health Plans (QHP) on Federally Facilitated Exchanges (FFEs)—to establish an electronic prior authorization process t...

Eric J. Small, MD, FASCO, Elected ASCO President for 2025–2026 Term

The ASCO Post Staff  /  January 25, 2024

ASCO has elected Eric J. Small, MD, FASCO, to lead as its President beginning in June 2025. Dr. Small, a long-time ASCO member and volunteer, will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 3, 2025. An additional six ASCO members were ele...

2023 ASCO Advocacy Highlights

ASCO  /  January 25, 2024

The Association for Clinical Oncology (ASCO) had an immensely impactful year of advocacy work, which is possible only with guidance and passion from our members. In partnership with the ASCO’s Government Relations Committee, five advocacy priorities were identified for the year: Protecting patien...

Lung Cancer

ASCO and Ontario Health Publish New Recommendations for Systemic Therapy in SCLC

Brandon May  /  December 25, 2023

A newly published guideline update from ASCO and Ontario Health provides evidence-based recommendations on the use of systemic therapy for small cell lung cancer (SCLC).1 Recommendations cover where novel agents fit in the treatment landscape, the management of disease in older patients with limited...

Neuroendocrine Tumors

New Guideline Offers Much-Needed Support in the Treatment of Neuroendocrine Tumors

Emily A. Kuhl, PhD  /  December 10, 2023

An ASCO guideline has been developed to inform the use of systemic treatments for metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).1 The guideline helps fill a knowledge gap among community oncologists in particular, who typically do not see many of these rare ...

Issues in Oncology

The Progress of Delivering High-Quality Cancer Care Takes Center Stage at Workshop

ASCO  /  November 25, 2023

ASCO and the National Cancer Policy Forum cohosted a workshop on October 5–6, 2023, to mark the 10-year anniversary of the Institute of Medicine (IOM) consensus report, Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis.1 The National Cancer Policy Forum is a convenin...

Kidney Cancer

ASCO Rapid Recommendation Update Cautions Against Triplet Therapy for Metastatic Clear Cell RCC

Emily A. Kuhl, PhD  /  November 25, 2023

An ASCO Rapid Recommendation Update advises oncologists to avoid the use of triple combination therapy for the management of metastatic clear cell renal cell carcinoma (RCC).1 The new guidance, which updates recommendations from the original 2022 guideline, reflects findings from a phase III, double...

Issues in Oncology

Association Urges Congress to Prioritize Childhood Cancer Funding, Research

ASCO  /  November 10, 2023

In honor of Childhood Cancer Awareness Month, the Association for Clinical Oncology (ASCO) joined with 25 stakeholders for a series of advocacy activities in Washington, DC, during the week of September 18. During meetings with lawmakers on September 20, ASCO and the Alliance for Childhood Cancer u...

Issues in Oncology

CMS, Congress Must Work Together to Support Access to Cancer Care and Physician Practice Health

ASCO  /  October 25, 2023

In letters to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) commented on provisions that impact cancer care for Medicare beneficiaries in the 2024 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) proposed rule, as well as...

Issues in Oncology

ASCO Response to Drug Shortages Request for Information

ASCO  /  October 25, 2023

The Association for Clinical Oncology (ASCO) responded to a bicameral Request for Information (RFI) on the underlying factors driving drug shortages. The Association’s comments highlighted the impact of the shortages on patient care and pointed to economic failures and supply chain vulnerabilities t...

Skin Cancer

Guideline Update Reflects Recent Surge of New Data in Systemic Therapy for Melanoma

Emily A. Kuhl, PhD  /  October 10, 2023

A guideline update on systemic treatment for melanoma offers new guidance in several areas, including the selection of front-line therapy for patients with metastatic disease with and without BRAF mutations, treatment of patients with earlier-stage disease in the adjuvant setting, and emerging neoad...

ASCO and State Affiliates Wrap Up Successful State Sessions

ASCO  /  October 10, 2023

After a fast-paced first half of the year, most state legislatures across the 50 states and Washington, DC, have adjourned for the year. The Association for Clinical Oncology (ASCO) and State Affiliates successfully collaborated to advance many shared 2023 state advocacy priorities, including those ...

Integrative Oncology

SIO and ASCO Partner to Develop Integrative Oncology Care Recommendations for Anxiety and Depression in Patients With Cancer

Mindy Tanzola  /  September 25, 2023

The Society for Integrative Oncology (SIO) and ASCO have partnered to develop a new guideline on integrative oncology care of symptoms of anxiety and depression in adults with cancer. The guideline reviews the evidence for a range of integrative approaches, including mindfulness-based interventions,...

ASCO Participates in President’s Cancer Panel

ASCO  /  September 25, 2023

ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support ...

Issues in Oncology
Solid Tumors

ASCO Releases Rapid Recommendation Update on Use of Olanzapine to Treat Cancer-Related Cachexia

LEAH LAWRENCE  /  September 25, 2023

ASCO recently released a new rapid recommendation update that addresses the use of olanzapine to treat cancer-related cachexia, a topic originally addressed in its 2020 guideline on the management of cancer cachexia in adults with advanced cancer.1,2 At that time, there was insufficient evidence to ...

Geriatric Oncology

ASCO Updates Guideline on Assessment, Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy

Brandon May  /  September 10, 2023

ASCO has updated a guideline on the practical assessment and management of age-associated vulnerabilities in older patients receiving systemic cancer therapy.1 Among the updates, the guideline adds more detail to domains that should be evaluated in geriatric assessments (GAs) and expands patient pop...

Breast Cancer

ASCO Awarded $11 Million to Study Oral Drug Dosing Strategies in Older Adults With Metastatic Breast Cancer Receiving CDK4/6 Inhibitors

ASCO  /  August 10, 2023

ASCO has been awarded $11 million in research funding by the Patient-Centered Outcomes Research Institute (PCORI) to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. The study aims to address a critical evidence gap in the treatment of this dise...

Lung Cancer

Rapid Guideline Update Offers Key Evidence-Based Recommendations for Stage III NSCLC Management

Brandon May  /  August 25, 2023

A new ASCO guideline rapid update provides updated recommendations for the management of stage III non–small cell lung cancer (NSCLC). These updated recommendations made by the ASCO expert panel cover treatment options for patients with resected disease and specific genetic mutations as well as ther...

Issues in Oncology

Cancer Care Providers Applaud New Federal Rule Regulating Short-Term Limited Duration Plans

ASCO  /  August 10, 2023

On July 7, 2023, the Department of Health and Human Services (HHS), Department of Labor, and the Treasury Department issued a proposed rule regulating the availability of short-term limited duration insurance plans. The rule would restrict the availability of these plans to no more than 4 months. ...

ASCO Issues Statements on Recent U.S. Supreme Court Rulings on Affirmative Action, LGBTQ+ Rights

ASCO  /  July 25, 2023

ASCO issued a statement regarding the U.S. Supreme Court decision on affirmative action on June 29. A statement from ASCO Chief Executive Officer, Clifford A. Hudis, MD, FASCO, FACP, follows: “[The] U.S. Supreme Court ruling on affirmative action threatens to reverse hard-won gains in diversity acr...

ASCO Blueprint Report Captures Steady Progress Toward Equity, Diversity, and Inclusion

ASCO  /  July 25, 2023

The American Society of Clinical Oncology (ASCO) has released its first-ever Equity, Diversity, and Inclusion (EDI) Blueprint Report, highlighting ASCO’s 2022 advancements in the EDI space. The report provides information on 22 initiatives that ASCO launched across the mission pillars of research, ...

Implementation of CLINICAL TREATMENT Act Advances, Increasing Access to Cancer Clinical Trials

ASCO  /  July 25, 2023

After direct advocacy from the Association for Clinical Oncology (ASCO) and its members, in December 2019, Congress enacted the CLINICAL TREATMENT Act, which requires all states and territories to cover and reimburse routine costs of care for treating a Medicaid enrollee who is participating in a qu...

Solid Tumors
Issues in Oncology

ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

Mindy Tanzola, PhD  /  July 10, 2023

Results from a series of randomized, controlled trials have prompted an update to the ASCO guideline on venous thromboembolism (VTE) prophylaxis and treatment in patients with cancer. The revised guideline, which had last been updated in 2019, is available from the Journal of Clinical Oncology.1 Ch...

Breast Cancer

Guideline Update Provides New Testing and Treatment Recommendations for Patients With ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Mutations

Wayne Kuznar  /  June 25, 2023

Testing for the emergence of ESR1 mutations should be routine at disease recurrence or progression for patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer whose disease is being managed with endocrine therapy, according to an ASCO guideline rapid recommendation upda...

Solid Tumors

ASCO Issues Clinical Guidance for Treating Gastrointestinal Cancers Amid Acute Drug Shortages

ASCO  /  June 25, 2023

ASCO has issued new clinical guidance for treating patients with gastrointestinal cancers amid a nationwide shortage of carboplatin and cisplatin. The two chemotherapy agents, in extremely short supply, are essential to treating an array of gastrointestinal cancers—such as esophageal, pancreatic, an...

Issues in Oncology

ASCO Updates Guideline for Management of Anxiety and Depression in Adult Cancer Survivors

MINDY TANZOLA, PhD  /  June 10, 2023

Cancer takes a significant psychological toll on affected individuals. Cancer survivors have a significantly elevated risk of developing a mental health disorder compared with the general population, yet their psychological symptoms are often underrecognized and undertreated. To help equip health-ca...

Issues in Oncology

ASCO Member Testifies Before Congress to Urge Significant Increase in Federal Cancer Research Funding

ASCO  /  June 10, 2023

The Association for Clinical Oncology (ASCO) continues to urge Congress to robustly fund the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Advanced Research Projects Agency for Health (ARPA-H) in Fiscal Year 2024. In testimony submitted to the Senate Committee on App...

ASCO Congratulates 2023 Special Awards Recipients

ASCO  /  May 25, 2023

ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award reci...

Lung Cancer

ASCO Releases Guideline Updates for Stage IV NSCLC With and Without Driver Alterations

Brandon May  /  May 10, 2023

ASCO has updated two living guidelines on the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations with the inclusion of new evidence-based treatment recommendations.1,2 Among the updates, the guidelines add the recently approved RAS GTPase family inh...

Issues in Oncology

ASCO Member Testifies Before Congress, Urging Significant Increase in Federal Cancer Research Funding

ASCO  /  April 25, 2023

Brian Persing, MD, a medical oncologist and hematologist in Mobile, Alabama, and a member of ASCO, the world’s leading professional organization representing nearly 45,000 oncology professionals, testified before the House Appropriations Subcommittee on Labor Health and Human Services and Educatio...

President Biden Prioritizes Cancer Research, Access to Care in FY 2024 Budget Proposal

ASCO  /  April 10, 2023

On March 9, 2023, President Joseph Biden released his proposed Fiscal Year (FY) 2024 federal budget, with an emphasis on increased funding for medical research and expanded access to health insurance. The proposal allocates $48.3 billion for the National Institutes of Health (NIH), an $811 millio...

Solid Tumors

EAU and ASCO Release Collaborative Guidelines on Penile Cancer

MINDY TANZOLA, PhD  /  April 10, 2023

Penile cancer is a rare disease with an incidence that is rising globally. Driven by a goal to offer clinicians and patients guidance on the management of this rare condition, ASCO collaborated with the European Association of Urology (EAU) to develop new guidelines on its diagnosis and treatment. A...

ASCO Celebrates the Cancer Moonshot on Its Relaunch Anniversary

ASCO  /  March 25, 2023

“Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of ...

Eight Oncology Health Systems Participating in Efforts to Improve Vaccination Rates Among High-Risk Adults

ASCO  /  March 25, 2023

ASCO is working with eight oncology health systems to develop, test, and measure strategies to improve immunization rates as part of an initiative with the Council of Medical Specialty Societies (CMSS) to improve vaccination rates among high-risk adults. Through this project, known as Specialty Soci...

2024 ACA Proposal Aims to Reduce Health-Care Coverage Gaps

ASCO  /  March 25, 2023

ASCO submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Patient Protection and Affordable Care Act 2024 Notice of Benefit and Payment Parameters proposed rule. ASCO’s comments support proposals aimed at reducing or eliminating gaps in health-care coverage, and ...

Three Models Testing Ways to Lower Drug Costs Outlined in Health and Human Services Report

ASCO  /  March 25, 2023

On February 14, 2023, the Centers for Medicare & Medicaid Services (CMS) announced that the Secretary of the Department of Health and Human Services (HHS) selected three models aiming to address high prescription drug costs for testing by the Center for Medicare and Medicaid Innovation (CMMI). T...

Breast Cancer
Immunotherapy

ASCO Updates Guideline on Sacituzumab Govitecan-hziy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Mindy Tanzola, PhD  /  March 25, 2023

ASCO has released a rapid recommendation update to the guideline on chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer, addressing the use of sacituzumab govitecan-hziy in patients with endocrine-resistant, hormone receptor–positive, HER2...

Gastroesophageal Cancer

First ASCO Guideline for Immunotherapy and Targeted Therapy in Advanced Gastroesophageal Cancer Now Available

MURIEL CUNNINGHAM  /  March 10, 2023

An ASCO expert panel has developed a comprehensive guideline for immunotherapy and targeted therapy in patients with advanced gastroesophageal cancer.1 The guideline is based on the many recent advances in immunotherapy and targeted therapy. “The role of immunotherapy has changed practice in the p...

Oncologists Applaud State of the Union’s Focus on Ending Cancer as We Know It

ASCO  /  March 10, 2023

Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO and the Association for Clinical Oncology, issued the following statement after President Joseph Biden’s State of the Union address on February 7. “ASCO applauds President Biden’s focus on ‘ending cancer as...

Issues in Oncology

Pilot Program Shows Diversity-Focused Clinical Trial Tools Are Useful at Cancer Research Sites

ASCO  /  March 10, 2023

Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published recently in JCO Oncology Practice.1,2 The studies examine the results from a collaborative pil...

New JCO Oncology Practice Special Series Highlights Current State of Team-Based Care, Innovations, and Future Direction

ASCO  /  February 10, 2023

What is team-based cancer care, and how has it evolved over the past decade? A special series in ASCO’s JCO Oncology Practice highlights transformations in team-based delivery models within the cancer care system and their potential direction. A carefully curated series of 15 peer-reviewed articles ...

Issues in Oncology

ASCO Formalizes Free Membership for Physicians in Lower-Middle–Income Countries

ASCO  /  February 10, 2023

The ASCO Board of Directors recently took further action to support members in lower-middle–income countries. In alignment with ASCO’s strategic goal of making a global impact, the Board elected to expand free membership for physicians from lower-middle–income countries, as defined by the World Bank...

Head and Neck Cancer
Immunotherapy

ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer

MINDY TANZOLA, PhD  /  February 10, 2023

A new ASCO guideline is available on the use of immunotherapy and biomarker testing for patients with recurrent or metastatic head and neck squamous cell carcinoma. The guideline provides recommendations related to PD-L1 and tumor mutational burden (TMB) testing, selection of therapy in the first-li...

Robin Zon Elected ASCO President for 2024–2025 Term; Other Leadership Positions Filled

ASCO  /  January 25, 2023

ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were elected to the ASCO Boar...

Former ASCO President Monica Bertagnolli Welcomed as NCI Director in Capitol Hill Reception

ASCO  /  January 25, 2023

On December 7, 2022, Association for Clinical Oncology (ASCO) Chief Medical Officer and Executive Vice President Julie Gralow MD, FACP, FASCO, attended a reception on Capitol Hill hosted by the One Voice Against Cancer Coalition and the House Cancer Caucus, to welcome former ASCO President Monica Be...

Issues in Oncology

ASCO Guideline Offers Recommendations on Prescribing Opioids to Patients With Cancer

AARON TALLENT  /  January 25, 2023

A new ASCO guideline on opioids in managing pain from cancer or cancer treatment in adults provides recommendations on administering them in the midst of interventions to address the public health crisis from their misuse and related deaths across the country.1 “ASCO took wonderful leadership in ...

Colorectal Cancer

ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic Colorectal Cancer

EMILY A. KUHL, PhD  /  December 10, 2022

A new ASCO guideline on the management of advanced colorectal cancer summarizes the latest treatments supported by quality data that could expand oncologists’ armamentarium and potentially improve survival outcomes.1 “[Colorectal cancer] remains the second-leading class of cancer deaths among m...

Updated Position Statement on Drug Repository Programs Aims to Increase Access to Treatment

ASCO  /  December 25, 2022

ASCO recently released an updated position statement on drug repository programs. The update shifts ASCO’s position to allow donation of oral cancer drug treatments in an open distribution system—which are drugs that have left the supply chain and have been dispensed to patients. ASCO’s previous po...

Nearly All Oncology Providers Report Prior Authorization Causing Delayed Care, Other Patient Harms

ASCO  /  December 25, 2022

Prior authorization is harming individuals with cancer, according to new survey results from ASCO. The survey found that prior authorization delays necessary care, worsens cancer care outcomes, and diverts clinicians from caring for their patients. Nearly all survey participants reported a patient ...

Advertisement

Advertisement




Advertisement